Anonymous
Guest
Anonymous
Guest
The first death knell sounded when VRUS started to show promise in 2010. 2011 saw INHX capitalize on this sweep and now BMS has added it's final piece to what will be an epic battle with GILD. This was never anything but a short-term run. Merck's HCV franchise will suffer the same fate as protease inhibitors are on their way out and qd one pill therapies are on the horizon.
Best of luck to all.
Best of luck to all.